Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Halliburton Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.65 (market cap $4.49B), while Halliburton Company trades at $35 (market cap $28.23B). The key difference: Halliburton Company is far larger — about 6.3× ACADIA Pharmaceuticals Inc.'s market cap, and Halliburton Company pays a 2.01% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HAL | |
|---|---|---|
Market Cap | $4.49B | $28.23B |
Sector | Health | Energy |
52-Week High | $28.06 | $42.98 |
52-Week Low | $20.06 | $20.50 |
Enterprise Value | $3.69B | $34.31B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Halliburton (HAL) trades at $33.79, up 2.52% today, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 18.23 and ROE of 14.56%, though 2025 revenue declined to $22.18B. Recent news highlights digital transformation partnerships and upcoming Q2 2026 earnings, while analyst consensus remains strongly bullish with a $44.22 price target.
HAL presents a compelling value opportunity with 30% upside to consensus target, supported by consistent earnings outperformance and strategic digital initiatives. Key risks include oil price volatility and competitive pressures in energy services. The stock's current discount to analyst targets and strong institutional support suggest potential for recovery despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
